Meta-analysis of surgery in advanced ovarian carcinoma: Is maximum cytoreductive surgery an independent determinant of prognosis?

American Journal of Obstetrics and Gynecology

Volumn 166, Issue 2, 1992, Pages 504-511

  William Hunter, R ^a   Alexander, Neal D E ^a   Patrick Soutter, W ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

advanced ovarian carcinoma; chemotherapy; Maximum cytoreductive surgery; prognosis

Indexed keywords

CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; MELPHALAN;

ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; FEMALE; HUMAN; META-ANALYSIS; OVARIAN NEOPLASMS; PLATINUM; PROGNOSIS; REGRESSION ANALYSIS; SURVIVAL RATE;

EID: 0026546910     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/0002-9378(92)91658-W     Document Type: Article

References (66)

1. Advanced ovarian cancer long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration
2. Long-term results of a cisplatin-containing combination chemotherapy regimen for the treatment of advanced ovarian carcinoma
3. Primary cytoreductive surgery for epithelial ovarian cancer
4. Intensive surgical and chemotherapeutic management of advanced ovarian cancer
5. Dose intensity analysis of chemotherapy regimens in ovarian carcinoma
6. The changing prognosis and treatment in cancer of the ovary
7. Variations in survival among patients with carcinoma of the ovary
8. Treatment of advanced epithelial ovarian cancer using cisplatin, Adramycin and cytoxan-the Indiana University experience
9. Randomized trial comparing two combination chemotherapy regimens (Hexa-CAF vs Chap-5) in advanced ovarian carcinoma
10. Advanced ovarian cancer: primary treatment with surgery, radiotherapy and chemotherapy
11. Surgery for common epithelial tumors of the ovary
12. The treatment of advanced ovarian carcinoma (1): clinical variables associated with prognosis
13. Advanced ovarian adenocarcinoma: a prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy
14. Review of ovarian cancer at the University of Texas Systems Cancer Center, M.D. Anderson Hospital and Tumor Institute
15. Hexamethylmelamine-an evaluation of its role in the treatment of ovarian cancer
16. Prognostic factors in malignant epithelial ovarian tumours
17. Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma
18. Clinical Oncology Society of Australia and the Sydney Branch Ludwig Institute for Cancer Research Chemotherapy of advanced ovarian adenocarcinoma a random
19. Randomized comparison of cisplatin with cyclophosphamide/cisplatin and with cyclophosphamide/doxorubicin/cisplatin in advanced ovarian cancer
20. High dose cisplatin compared with high dose cyclophosphamide in the management of advanced epithelial ovarian cancer (FIGO stages III and IV): report from the
21. Cyclophosphamide plus cis-platinum in combination: treatment program for stage III or IV ovarian carcinoma
22. Cisplatin regimens and improved prognosis of patients with poorly differentiated ovarian cancer
23. Medical Research Council Study on chemotherapy in advanced ovarian cancer
24. Cytoreduction in ovarian cancer: achievability and results
25. A prospective and randomized clinical trial of cyclophosphamide versus combination cytotoxic chemotherapy (Hexa-CAF)
26. Hexamethylmelamine, Adriamycin and Cyclophosphamide (HAC) versus Cisdichlorodiamineplatinum, Adriamycin and cyclophos phamide (PAC) in advanced ovarian cancer
27. Cis-platinum Adriamycin and hexamethylmelamine versus cyclophosphamide in advanced ovarian cancer
28. Chemotherapy of advanced ovarian carcinoma: initial experience using a platinum-based combination
29. Improved chemotherapy for ovarian cancer with cis-diamminedichloroplatinum and Adriamycin
30. Cis-platin based combination chemotherapy for advanced ovarian cancer
31. Advanced ovarian cancer: a prospective randomized trial of chlorambucil versus combined cyclophosphamide and cis-diamminedichloroplatinum
32. Comparison of melphalan with cyclophosphamide, methotrexate and 5-fluorouracil in patients with ovarian cancer
33. Modulation and intensification of a cyclophosphamide, hexamethylmelamine, doxorubicin and cisplatin ovarian cancer regimen
34. Treat-ment of advanced epithelial ovarian cancer with cisplatin and cyclophosphamide
35. Randomized trial comparing prednimustine with combination chemotherapy in advanced ovarian carcinoma
36. A prospective randomized clinical trial of melphalan and cis-platinum versus hexamethylmelamine, Adriamycin and cyclophosphamide in advanced ovarian cancer
37. Adriamycin and cisplatin in the treatment of stage III and IV epithelial ovarian cancer
38. Infusional cisplatin plus cyclophosphamide in advanced ovarian cancer
39. Single-agent cisplatinum therapy for advanced ovarian cancer
40. Singleagent Adriamycin followed by combination hexamethylmelamine-cyclophosphamide for advanced ovarian carcinoma
41. High-dose cyclophosphamide followed by cisplatinum in the treatment of ovarian cancer
42. Advanced ovarian cancer: three-year results of a 6-8 month, 2-drug cisplatincontaining regimen
43. Treatment of advanced ovarian cancer with sequential combination chemotherapy
44. A randomized study of cyclophosphamide and cis-platinum with orwithout doxorubicin in advanced ovarian carcinoma
45. Comparison of cyclophosphamide plus cisplatin versus hexabination chemotherapy versus chlorambucil in advanced ovarian carcinoma: mature results of a randomiz
46. Adriamycin and cisplatinum in advanced ovarian cancer
47. Ten-year follow-up of patients receiving cisplatin, doxorubicin and cyclophosphamide chemother apy for advanced epithelial ovarian carcinoma
48. High-doseintensity regimen of weekly doxorubicin and cisplatin in the treatment of patients with stage III and IV epithelial ovarian cancer
49. The impact of aggressive debulking surgery and cisplatin-based chemotherapy on progression-free survival in stage III and IV ovarian carcinoma
50. The treatment of 48 patients affected by ovarian carcinoma at stages III and IV FIGO
51. Alternating combination chemotherapy for stages III and IV ovarian carcinoma
52. Sequential chemotherapy for advanced epithelial ovarian cancer: platinum combination cytoreduction followed by cyclophosphamide consolidation
53. Primary or delayed debulking surgery and chemotherapy consisting of cisplatin, doxorubicin and cyclophosphamide in stage III-IV epithelial ovarian cancer
54. A prospective randomized trial comparing high-dose cisplatin with low-dose cisplatin and chlorambucil in advanced ovarian carcinoma
55. Cisplatin combination chemotherapy versus chloramducil in advanced ovarian carcinoma: mature results of a randomized trial.
56. Chemotherapeutic and surgical induction of a pathological complete remission and whole abdominal irradiation for consolidation does not enhance the cure of st
57. Long-term survival rates with various chemotherapeutic regimens in stages I l I and IV ovarian adenocarcinoma
58. The role of lymphadenectomy in ovarian cancer
59. A simple method for evaluating the ShapiroFrancia W' test for non-normality
60. Randomised cancer trials-past failures, current progress and future prospects?
61. Lower urinary tract resection as part of cytoreductive surgery for ovarian cancer
62. The Will Rogers phenomenon: stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer
63. Debulking surgery: does it increase the quality of survival?